A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cellular senescence is a key mechanism for tumor suppression, inducing cell growth arrest and immune responses.
• Current senescence-inducing therapies lack selectivity, affecting healthy cells alongside cancerous ones.
• Targeting specific pathways to selectively induce senescence in tumors is crucial for effective cancer treatment.

Purpose of the Study:

• To identify compounds and targets that selectively induce cellular senescence in PTEN-deficient cancer cells.
• To elucidate the molecular mechanisms underlying senescence induction in PTEN-deficient tumors.
• To explore the potential of targeting the identified pathway for novel cancer therapies.

Main Methods:

• Utilized chemogenomic screening to identify pro-senescence compounds in PTEN-deficient cells.
• Investigated the role of casein kinase 2 (CK2) as a potential therapeutic target.
• Analyzed the STAT3-CK2-PML signaling network in the context of Pten loss and senescence.

Main Results:

• Identified CK2 as a pro-senescent target in PTEN-deficient cells.
• Demonstrated that Pten loss activates STAT3, leading to increased CK2 levels.
• Showed that CK2 upregulation destabilizes PML, and CK2 inhibition stabilizes PML, enhancing senescence in Pten-null tumors.

Conclusions:

• A novel STAT3-CK2-PML signaling network was identified as critical for regulating senescence in PTEN-deficient cancers.
• Targeting CK2 offers a selective strategy to enhance senescence and promote anti-tumor immunity.
• This network presents a promising therapeutic avenue for developing selective pro-senescence cancer treatments.